Since its outbreak in China late last year, the Communist pneumonia epidemic has become a global pandemic, resulting in at least 142.83 million confirmed cases and 3.046 million deaths. Many countries have implemented mass vaccination programs against Wuhan pneumonia. China has received more than 200 million doses of vaccine to date, but Gao Fu, director of the Chinese Center for Disease Control and Prevention, recently admitted that China’s vaccine protection is low. However, as to whether people who have received the vaccine need to continue to be re-injected afterwards, Shao Yiming, a researcher at the CDC, said on the 21st that the new Chinese domestic crown vaccine is now effective for about six months, and the exact timing of the re-injection is still under study.
Shao Yiming pointed out that for the vaccine effective time, currently in about six months, various vaccine manufacturers, including various national immunization planning departments are studying these data. The decision on when a booster is needed has to be made scientifically based on the data, and it is possible that it will need to be booster every year, like other diseases transmitted by the respiratory tract, such as influenza, which is subject to the analysis of the final data. Asked about claims that the global mass rollout of Wuhan pneumonia vaccination could prompt accelerated mutation of the virus and that an immune escape response to the virus could occur. Shao Yiming said, “This claim should lack scientific basis.”
Shao Yiming stressed that the vaccine can block the spread of the virus, the virus cannot replicate when it does not spread, and if it cannot replicate, it will not produce more mutant strains, in which case the vaccine is absolutely positive and will not promote the emergence of more mutant strains. By promoting the vaccine on a large scale, we can still buy time for future virus mutations to occur, so that companies and R&D institutions can research a new generation of vaccines for mutated strains in response to the emergence of mutations. In this sense, the vaccine can definitely prevent the emergence of mutated strains, rather than promote their emergence.
Mi Feng, spokesperson of the National Health and Welfare Commission of China, mentioned that some people in China have recently reported the difficulty of making appointments for the second dose. Li Dachuan, deputy director of the Medical Affairs and Medical Bureau of China’s National Health Commission, pointed out that medical workers are on the front line of regular epidemic prevention and control, and are one of the key populations for vaccination against the new crown vaccine. Up to now, the vaccination rate of medical workers in China has exceeded 80% for the common pneumonia vaccine.
Recent Comments